180 related articles for article (PubMed ID: 25160476)
41. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
42. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
43. Basic nuclear processes affected by histone acetyltransferases and histone deacetylase inhibitors.
Legartová S; Stixová L; Strnad H; Kozubek S; Martinet N; Dekker FJ; Franek M; Bártová E
Epigenomics; 2013 Aug; 5(4):379-96. PubMed ID: 23895652
[TBL] [Abstract][Full Text] [Related]
44. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
Marks PA; Breslow R
Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
[TBL] [Abstract][Full Text] [Related]
45. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
46. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
47. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
49. Alterations in histone acetylation following exposure to
Tian XL; Lu X; Feng JB; Cai TJ; Li S; Tian M; Liu QJ
Radiat Environ Biophys; 2018 Aug; 57(3):215-222. PubMed ID: 29774413
[TBL] [Abstract][Full Text] [Related]
50. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
[TBL] [Abstract][Full Text] [Related]
51. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
52. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
53. Histone deacetylase inhibitors induce mitochondrial elongation.
Lee JS; Yoon YG; Yoo SH; Jeong NY; Jeong SH; Lee SY; Jung DI; Jeong SY; Yoo YH
J Cell Physiol; 2012 Jul; 227(7):2856-69. PubMed ID: 21928346
[TBL] [Abstract][Full Text] [Related]
54. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
55. Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma.
Zrimšek M; Kuchaříková H; Draganić K; Dobrovolná P; Heiss Spornberger V; Winkelmayer L; Hassler MR; Lochmanová G; Zdráhal Z; Egger G
Cells; 2022 Aug; 11(15):. PubMed ID: 35954222
[TBL] [Abstract][Full Text] [Related]
56. Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells.
Li JY; Tian T; Han B; Yang T; Guo YX; Wu JY; Chen YS; Yang Q; Xie RJ
World J Gastroenterol; 2023 Sep; 29(34):5038-5053. PubMed ID: 37753370
[TBL] [Abstract][Full Text] [Related]
57. Ultradeep Lysine Crotonylome Reveals the Crotonylation Enhancement on Both Histones and Nonhistone Proteins by SAHA Treatment.
Wu Q; Li W; Wang C; Fan P; Cao L; Wu Z; Wang F
J Proteome Res; 2017 Oct; 16(10):3664-3671. PubMed ID: 28882038
[TBL] [Abstract][Full Text] [Related]
58. Dynamics and functional interplay of histone lysine butyrylation, crotonylation, and acetylation in rice under starvation and submergence.
Lu Y; Xu Q; Liu Y; Yu Y; Cheng ZY; Zhao Y; Zhou DX
Genome Biol; 2018 Sep; 19(1):144. PubMed ID: 30253806
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibition regulates miR-449a levels in skeletal muscle cells.
Poddar S; Kesharwani D; Datta M
Epigenetics; 2016 Aug; 11(8):579-87. PubMed ID: 27184529
[TBL] [Abstract][Full Text] [Related]
60. Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells.
Zhu X; Liu X; Cheng Z; Zhu J; Xu L; Wang F; Qi W; Yan J; Liu N; Sun Z; Liu H; Peng X; Hao Y; Zheng N; Wu Q
Sci Rep; 2016 Jan; 6():19926. PubMed ID: 26822725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
